Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Oxford Biomedica Plc LSE:OXB London Ordinary Share GB00BDFBVT43 ORD 50P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  9.50 2.57% 379.50 375.50 380.50 386.50 360.00 360.00 233,633 16:29:59
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 142.8 19.9 22.8 16.7 365

Oxford Biomedica PLC Total Voting Rights

01/09/2022 9:51am

UK Regulatory (RNS & others)


Oxford Biomedica (LSE:OXB)
Historical Stock Chart


From Sep 2022 to Dec 2022

Click Here for more Oxford Biomedica Charts.

TIDMOXB

RNS Number : 9347X

Oxford Biomedica PLC

01 September 2022

Oxford Biomedica

Total Voting Rights

Oxford, UK - 01 September 2022: Oxford Biomedica plc (LSE:OXB) ("Oxford Biomedica" or "the Company"), a leading gene and cell therapy group, today announces that in accordance with the FCA's Disclosure Guidance and Transparency Rule 5.6.1, the Company's issued share capital as at the close of business on 31 August 2022 consisted of 96,213,346 ordinary shares of 50 pence each ("Ordinary Shares"). There are no Ordinary Shares held in treasury.

Accordingly, the total number of voting rights in Oxford Biomedica plc at the date of this notice is 96,213,346 .

The above figure ( 96,213,346 ) may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, Oxford Biomedica plc under the FCA's Disclosure Guidance and Transparency Rules.

-Ends-

 
 For further information, please 
  contact: 
 
   Oxford Biomedica plc:                 Tel: +44 (0)1865 783 000 
   Natalie Walter, Company Secretary 
 

About Oxford Biomedica

Oxford Biomedica (LSE: OXB) is an innovative leading viral vector specialist focused on delivering life changing therapies to patients.

Oxford Biomedica plc and its subsidiaries (the Group) work across key viral vector delivery systems including those based on lentivirus, adeno-associated virus (AAV) and adenovirus, providing innovative solutions to cell and gene therapy biotechnology and biopharma companies for their process development, analytical development, and manufacturing needs. Oxford Biomedica has built a sector leading lentiviral vector delivery system, LentiVector(R) platform, which the Group leverages to develop product candidates in-house, before seeking partners to take the products into clinical trials.

Oxford Biomedica is based across several locations and headquartered in Oxfordshire, UK. In early 2022, the Group established Oxford Biomedica Solutions, a new US based subsidiary AAV manufacturing and innovation business, based near Boston, US.

Oxford Biomedica employs more than 940 people. Further information is available at www.oxb.com .

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

TVREAPNFELNAEEA

(END) Dow Jones Newswires

September 01, 2022 04:51 ET (08:51 GMT)

1 Year Oxford Biomedica Chart

1 Year Oxford Biomedica Chart

1 Month Oxford Biomedica Chart

1 Month Oxford Biomedica Chart
Your Recent History
LSE
OXB
Oxford Bio..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

Log in to ADVFN
Register Now

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:gb D:20221201 06:52:47